Dysplasia in inflammatory bowel disease

Area of Science:

• Gastroenterology
• Oncology
• Pathology

Background:

• Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's colitis, significantly elevates the risk of colorectal neoplasia.
• Cancer risk escalates with disease duration and extent, particularly after 8-10 years in extensive or pancolitis cases.
• Childhood onset and primary sclerosing cholangitis are additional risk factors for colorectal carcinoma in IBD patients.

Purpose of the Study:

• To outline the current management strategies for neoplasia surveillance in ulcerative colitis and Crohn's colitis.
• To emphasize the critical role of endoscopic surveillance and accurate pathological assessment of dysplasia.
• To guide clinical decision-making regarding prophylactic colectomy based on dysplasia grading.

Main Methods:

• Systematic review of current literature and clinical guidelines on IBD-associated neoplasia surveillance.
• Analysis of diagnostic criteria for dysplasia in endoscopic biopsies.
• Evaluation of management recommendations, including prophylactic colectomy thresholds.

Main Results:

• Surveillance endoscopy with biopsy is the primary strategy for detecting dysplastic precursor lesions.
• Accurate classification of biopsies into negative, indefinite, low-grade, or high-grade dysplasia is essential.
• High-grade dysplasia or low-grade dysplasia with a mass warrants prophylactic colectomy; some centers extend this to flat mucosa low-grade dysplasia.

Conclusions:

• Careful interpretation of biopsies is necessary to avoid overcalling reactive changes in active colitis.
• Confirmation of dysplasia diagnoses by experienced gastrointestinal pathologists is strongly recommended.
• Adherence to established surveillance protocols and diagnostic criteria can mitigate the risk of colorectal cancer in IBD patients.